GLP-2 TIRZCheck methods and identity
What an antibody add-on study measured besides weight
2 numbered sourcesSource years 2022, 2026
Peptides are short chains of amino acids connected by peptide bonds. Some work by activating receptors that respond to hormones released after eating. Tirzepatide is a peptide that activates GIP and GLP-1 receptors. The “GLP-2” wording in the catalog label does not correspond to a receptor target. The 2026 EMBRAZE trial asked whether adding the investigational antibody apitegromab changed lean mass in adults receiving tirzepatide for weight reduction. [1, 2]
Apitegromab is a monoclonal antibody designed to inhibit activation of myostatin, a protein involved in regulating muscle growth. Investigators randomized 102 adults with overweight or obesity to receive tirzepatide with apitegromab or tirzepatide with a placebo for the antibody. Tirzepatide was present in both groups. The design therefore isolated the comparison of adding the specified antibody against adding an inactive control. It could not show what the antibody would do on its own in those participants. [1]
At 24 weeks, the antibody group had about 1.9 kilograms less lean mass loss on average than the group receiving tirzepatide with placebo, despite a similar total body weight change. Lean mass represents the measured mass other than fat, and it includes more than skeletal muscle alone. A change in lean mass is different from a change in strength, walking ability or performance on a task. That distinction matters because each of these measures can answer a different question about function. [1]
The study reported generally similar proportions of adverse events between the groups. One participant in each group experienced a serious adverse event. With only 51 people assigned to each arm, the study gives limited information about uncommon or longer-term events. Its main finding is an early body composition comparison for this specific antibody and peptide combination. It cannot be transferred to a different antibody or to a growth factor simply because those compounds also appear in research on body composition. [1]
This is a case where average scale weight and a measure of tissue composition tell different parts of the story. The observed difference depended on which antibody the investigators added and which groups they compared. Later studies can ask how any change in lean tissue relates to outcomes that matter in daily life, such as strength or mobility. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
